Key result
Polycystic ovarian syndrome is associated with a pro-atherogenic risk factor profile, but it has not been clearly demonstrated that this translates into increased cardiovascular morbidity and mortality.
While PCOS is associated with adverse metabolic risk factors like dyslipidemia and insulin resistance, it remains unclear if this increases cardiovascular morbidity and mortality.
Polycystic ovarian syndrome is a common endocrine disorder of women. It is associated with an adverse metabolic risk factor profile including hyperinsulinemia, abnormal glucose metabolism, dyslipidemia and chronic pro-atherogenic low grade inflammation. A large proportion of PCOS women are overweight or obese; these women have a high prevalence of insulin resistance and some studies suggest this also the case in lean women with PCOS. Impaired glucose tolerance and diabetes are more common in women with PCOS than in the general population. Besides conventional atherogenic dyslipidemia, PCOS women have additional abnormalities including elevations in small, dense LDL and dysfunctional HDL-particles. Despite a clear pro-atherogenic risk factor profile, it has not been clearly demonstrated that this translates into increased cardiovascular morbidity and mortality in this population.
No takes yet. Share an insight, caveat, or question.
Pazderska et al. (2015) conducted a review in Polycystic ovarian syndrome. Polycystic ovarian syndrome vs. General population was evaluated. Polycystic ovarian syndrome is associated with a pro-atherogenic risk factor profile, but it has not been clearly demonstrated that this translates into increased cardiovascular morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: